The ESMO congress always disseminates the latest ... EVP, EVERSANA COMPLETE Oncology, EVERSANA; Barry Vucsko, Senior Vice President, Client Services and Business Development Leader, EVERSANA ...

Over the next few years, the promise is that a broader field of immuno-oncology drugs will ... The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the ...

at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024 taking place 11-13 December in Geneva, Switzerland. Presentation details: Abstracts will be made available on ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Welcome to Medscape's ESMO 2017 Live Blog. Throughout the ESMO 2017 Congress in Madrid, experts from across a range of cancer tumor types will provide real-time coverage of the most important ...

The European Society for Medical Oncology holds an annual congress where scientists ... about the research our scientists have presented at the congress over the years. ESMO Virtual Plenary 2022: ...

The company is now advancing into immuno-oncology (IO), led by Timo van den Berg, Senior Director of Immuno-Oncology, and Wim Dokter, Chief Scientific Officer. Byondis’ lead cancer ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

In recent years, immuno-oncology has redefined cancer treatment by harnessing the body's immune system to fight cancer more effectively. With traditional treatments often falling short in advanced ...

additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO Immuno-Oncology Annual Congress ...

Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society for Medical Oncology) update. 3-year performance isn't looking much better at -81% ...